270 related articles for article (PubMed ID: 29041946)
1. The role of B cell antigen receptors in mantle cell lymphoma.
Fichtner M; Dreyling M; Binder M; Trepel M
J Hematol Oncol; 2017 Oct; 10(1):164. PubMed ID: 29041946
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
Xargay-Torrent S; López-Guerra M; Montraveta A; Saborit-Villarroya I; Rosich L; Navarro A; Pérez-Galán P; Roué G; Campo E; Colomer D
Clin Cancer Res; 2013 Feb; 19(3):586-97. PubMed ID: 23231952
[TBL] [Abstract][Full Text] [Related]
3. LRPAP1 is a frequent proliferation-inducing antigen of BCRs of mantle cell lymphomas and can be used for specific therapeutic targeting.
Thurner L; Hartmann S; Fadle N; Kemele M; Bock T; Bewarder M; Regitz E; Neumann F; Nimmesgern A; von Müller L; Pott C; Kim YJ; Bohle RM; Wasik M; Schuster SJ; Hansmann ML; Preuss KD; Pfreundschuh M
Leukemia; 2019 Jan; 33(1):148-158. PubMed ID: 29955130
[TBL] [Abstract][Full Text] [Related]
4. Concomitant high expression of Toll-like receptor (TLR) and B-cell receptor (BCR) signalling molecules has clinical implications in mantle cell lymphoma.
Akhter A; Street L; Ghosh S; Burns BF; Elyamany G; Shabani-Rad MT; Stewart DA; Mansoor A
Hematol Oncol; 2017 Mar; 35(1):79-86. PubMed ID: 26354285
[TBL] [Abstract][Full Text] [Related]
5. Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma.
Saba NS; Liu D; Herman SE; Underbayev C; Tian X; Behrend D; Weniger MA; Skarzynski M; Gyamfi J; Fontan L; Melnick A; Grant C; Roschewski M; Navarro A; Beà S; Pittaluga S; Dunleavy K; Wilson WH; Wiestner A
Blood; 2016 Jul; 128(1):82-92. PubMed ID: 27127301
[TBL] [Abstract][Full Text] [Related]
6. Advances in Molecular Biology and Targeted Therapy of Mantle Cell Lymphoma.
Klener P
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500350
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
8. Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling.
Pighi C; Gu TL; Dalai I; Barbi S; Parolini C; Bertolaso A; Pedron S; Parisi A; Ren J; Cecconi D; Chilosi M; Menestrina F; Zamò A
Cell Oncol (Dordr); 2011 Apr; 34(2):141-53. PubMed ID: 21394647
[TBL] [Abstract][Full Text] [Related]
9. SOX11 augments BCR signaling to drive MCL-like tumor development.
Kuo PY; Jatiani SS; Rahman AH; Edwards D; Jiang Z; Ahr K; Perumal D; Leshchenko VV; Brody J; Shaknovich R; Ye BH; Parekh S
Blood; 2018 May; 131(20):2247-2255. PubMed ID: 29615403
[TBL] [Abstract][Full Text] [Related]
10. B-cell receptor signaling activity identifies patients with mantle cell lymphoma at higher risk of progression.
Gambino S; Quaglia FM; Galasso M; Cavallini C; Chignola R; Lovato O; Giacobazzi L; Caligola S; Adamo A; Putta S; Aparo A; Ferrarini I; Ugel S; Giugno R; Donadelli M; Dando I; Krampera M; Visco C; Scupoli MT
Sci Rep; 2024 Mar; 14(1):6595. PubMed ID: 38503806
[TBL] [Abstract][Full Text] [Related]
11. miR-17-92 cluster-BTG2 axis regulates B-cell receptor signaling in mantle cell lymphoma.
Kawaji-Kanayama Y; Tsukamoto T; Nakano M; Tokuda Y; Nagata H; Mizuhara K; Katsuragawa-Taminishi Y; Isa R; Fujino T; Matsumura-Kimoto Y; Mizutani S; Shimura Y; Taniwaki M; Tashiro K; Kuroda J
Cancer Sci; 2024 Feb; 115(2):452-464. PubMed ID: 38050664
[TBL] [Abstract][Full Text] [Related]
12. Mantle cell lymphoma: taking therapeutic advantage of new insights into the biology.
Tang T; Martin P
Curr Hematol Malig Rep; 2014 Sep; 9(3):254-61. PubMed ID: 25023397
[TBL] [Abstract][Full Text] [Related]
13. The molecular pathogenesis of mantle cell lymphoma.
Vogt N; Dai B; Erdmann T; Berdel WE; Lenz G
Leuk Lymphoma; 2017 Jul; 58(7):1530-1537. PubMed ID: 27894215
[TBL] [Abstract][Full Text] [Related]
14. CD40L mediated alternative NFκB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma.
Rauert-Wunderlich H; Rudelius M; Berberich I; Rosenwald A
Cell Death Dis; 2018 Jan; 9(2):86. PubMed ID: 29367645
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in mantle cell lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop.
Williams ME; Bernstein SH; Jares P; Kahl BS; Witzig TE; Gordon LI
Leuk Lymphoma; 2013 Sep; 54(9):1882-90. PubMed ID: 23363271
[TBL] [Abstract][Full Text] [Related]
16. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
17. The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.
Arkwright R; Pham TM; Zonder JA; Dou QP
Expert Opin Drug Discov; 2017 Feb; 12(2):225-235. PubMed ID: 27917682
[TBL] [Abstract][Full Text] [Related]
18. Mantle cell lymphoma in relapse: the role of emerging new drugs.
Diefenbach CS; O'Connor OA
Curr Opin Oncol; 2010 Sep; 22(5):419-23. PubMed ID: 20679769
[TBL] [Abstract][Full Text] [Related]
19. Novel therapies in mantle cell lymphoma: a pathway to chemotherapy-free strategies.
Nastoupil LJ; Koff JL; Flowers CR
Oncology (Williston Park); 2013 Oct; 27 Suppl 2():8-12. PubMed ID: 25374999
[TBL] [Abstract][Full Text] [Related]
20. Targeting B-cell receptor signaling: changing the paradigm.
Fowler N; Davis E
Hematology Am Soc Hematol Educ Program; 2013; 2013():553-60. PubMed ID: 24319231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
